Orexo AB (LTS:0H19) Tariff Resilience Score: 0/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H19 Orexo AB LTS:0H19
47 GF Score
Price kr15.43
GF Value kr3.76
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Tariff Resilience Score?

Orexo AB has the Tariff Resilience Score of 0, which implies that the company might have .

Orexo AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Orexo AB might have .

Orexo AB  (LTS:0H19) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Orexo AB Tariff Resilience Score Related Terms

LTS:0H19
47GF Score
Orexo AB LTS:0H19
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orexo AB (LTS:0H19) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr15.43 is trading 310.4% above its estimated GF Value™ of kr3.76. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for LTS:0H19:

  • Tariff Resilience Score: 0
  • GF Value™: kr3.76 vs. price of kr15.43 (310.4% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the LTS:0H19 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
47GF Score

Get the complete analysis for LTS:0H19

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.43
Price
kr3.76
GF Value